The grant will support a Phase I study of an anti-CD64 CAR T-cell therapy in patients with acute myeloid leukemia.

The partners want to develop personalized therapeutics and diagnostics based on insights derived from the Middle Eastern biorepository.

The trials will test the ability of the firm's fluorine-18 labeled PET tracer to detect FAP-expressing tumor cells in ...

The firm at the JP Morgan Healthcare Conference additionally expects a regulatory decision on its gene therapy RGX-121 for Hunter syndrome next month.

Researchers will use a quantitative continuous scoring platform to measure patients' tumors for TROP2 expression in the trial.

The firm hopes to become a commercial-stage company this year, if the KIT inhibitor bezuclastinib is approved by the FDA as expected.

Genethon has licensed to AskBio a component of a preclinical gene therapy approach for treating Pompe disease.

The firm said at the JP Morgan Healthcare Conference that it wants zorevunersen to be approved as a disease-modifying ...

The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.

The firm is focused on helping pharma characterize response and resistance to their drugs, with the hope of getting a companion diagnostic approval.

The firm expects a first readout from an investigator-initiated trial of an in vivo CAR T-cell therapy in the second half of this year.